Invasive Prenatal Diagnostics: A Cornerstone of Perinatal Management
Source abstract
Abstract
Since the 1950s, invasive prenatal diagnostics have played an integral role in perinatal management. However, its significance extends beyond detecting genetic abnormalities. This paper comprehensively reviews the indications for amniocentesis and chorionic villus sampling. Additionally, it examines various methods of genomic, infectious, and biochemical analysis, with a particular emphasis on the achievements of the last decade.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Prenatal Screening and Diagnostics · Congenital Anomalies and Fetal Surgery · Parvovirus B19 Infection Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Reproduction, Poznan University of Medical Sciences, 61-712 Poznań, Poland
Student’s Scientific Society, Department of Medicine, Poznan University of Medical Sciences, 61-712 Poznań, Poland
References (100+)
Show source-provided references
1. Antenatal Sex Determination10.1038/177330a0 ↗
2. The diagnosis of sex before birth using cells from the amniotic fluid (a preliminary report)
3. Diagnosis of sex before birth10.1016/S0140-6736(56)90532-3 ↗
4. Nuclear morphology of cells in human amniotic fluid in relation to sex of infant10.1016/0002-9378(56)90579-8 ↗
5. Detection of sex of fetuses by the incidence of sex chromatin body in nuclei of cells in amniotic fluid10.1126/science.123.3196.542.b ↗
6. Sexing fœtuses by examination of amniotic fluid10.1016/S0140-6736(56)91766-4 ↗
7. Chromosome analysis of human amniotic-fluid cells10.1016/S0140-6736(66)91387-0 ↗
8. Intrauterine diagnosis and management of genetic defects10.1016/0002-9378(67)90395-X ↗
9. Obstetric radiology10.1136/pgmj.46.531.32 ↗
10. Intravenous Placentography10.1148/80.4.654 ↗
11. Malignant disease in childhood and diagnostic irradiation in utero10.1016/S0140-6736(56)91923-7 ↗
12. A Survey of Childhood Malignancies10.1136/bmj.1.5086.1495 ↗
13. Changes in the cancer risk associated with obstetric radiography10.1016/S0140-6736(68)92719-0 ↗
14. Incidence of Leukaemia after Exposure to Diagnostic Radiation in Utero10.1136/bmj.2.5212.1539 ↗
15. Investigation of abdominal masses by pulsed ultrasound10.1016/S0140-6736(58)91905-6 ↗
16. A Short History of Sonography in Obstetrics and Gynaecology
17. Fetal development as determined by ultrasonic pulse echo techniques10.1016/0002-9378(65)90103-1 ↗
18. Intrauterine growth assessed by ultrasonic foetal cephalometry10.1111/j.1471-0528.1967.tb03774.x ↗
19. The prediction of fetal maturity by ultrasonic measurement of the biparietal diameter10.1111/j.1471-0528.1969.tb06146.x ↗
20. Ultrasonic measurement of fetal abdomen circumference in the estimation of fetal weight10.1111/j.1471-0528.1975.tb00708.x ↗
21. Sonar Measurement of Fetal Crown-Rump Length as Means of Assessing Maturity in First Trimester of Pregnancy10.1136/bmj.4.5883.28 ↗
22. Anencephaly: Early ultrasonic diagnosis and active management10.1016/S0140-6736(72)92273-8 ↗
23. Early prenatal diagnosis of neural tube defects by ultrasound10.1097/00003081-197706000-00015 ↗
24. Estimation of fetal weight with the use of head, body, and femur measurements—A prospective study10.1016/0002-9378(85)90298-4 ↗
25. A sonographic sign for the detection in the second trimester of the fetus with Down’s syndrome10.1016/0002-9378(85)90385-0 ↗
26. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy10.1136/bmj.304.6831.867 ↗
27. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 11–13 weeks of gestation10.1046/j.1469-0705.1996.07040245.x ↗
28. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10–14 weeks of gestation10.1046/j.1469-0705.1998.11060391.x ↗
29. Screening for chromosomal abnormalities at 10–14 weeks: The role of ductus venosus blood flow10.1046/j.1469-0705.1998.12060380.x ↗
30. Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: An observational study10.1016/S0140-6736(01)06709-5 ↗
31. Tricuspid regurgitation in the diagnosis of chromosomal anomalies in the fetus at 11–14 weeks of gestation10.1136/heart.89.9.1071 ↗
32. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A10.1046/j.1469-0705.1999.13040231.x ↗
33. One-stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: A prospective study of 15 030 pregnancies10.1046/j.1469-0705.2002.00808.x ↗
34. One stop clinic for assessment of risk for fetal anomalies: A report of the first year of prospective screening for chromosomal anomalies in the first trimester10.1111/j.1471-0528.2000.tb11619.x ↗
35. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation10.1002/uog.6318 ↗
36. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation10.1002/uog.6264 ↗
37. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation10.1002/uog.6330 ↗
38. Accuracy of First-Trimester Combined Test in Screening for Trisomies 21, 18 and 1310.1097/OGX.0000000000000500 ↗
39. Antenatal screening for chromosomal abnormalities10.1007/s00404-022-06477-5 ↗
40. Systematic review of first-trimester ultrasound screening for detection of fetal structural anomalies and factors that affect screening performance10.1002/uog.17246 ↗
41. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks10.1002/pd.2642 ↗
42. Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on first-trimester screening for chromosomal abnormalities10.1002/uog.17286 ↗
43. Diagnosis of Fetal Structural Anomalies at 11 to 14 Weeks10.1002/jum.14561 ↗
44. ISUOG Practice Guidelines: Performance of first-trimester fetal ultrasound scan10.1002/uog.12342 ↗
45. International Society of Ultrasound in Obstetrics and Gynecology, Bilardo, C.M., Chaoui, R., Hyett, J.A., Kagan, K.O., Karim, J.N., Papageorghiou, A.T., Poon, L.C., Salomon, L.J., and Syngelaki, A. (2023). ISUOG Practice Guidelines (updated): Performance of 11–14-week ultrasound scan. Ultrasound Obstet. Gynecol., 61, 127–143.10.1002/uog.26106 ↗
46. Presence of fetal DNA in maternal plasma and serum10.1016/S0140-6736(97)02174-0 ↗
47. Sequencing of Circulating Cell-free DNA during Pregnancy10.1056/NEJMra1705345 ↗
48. Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening10.1007/s00247-017-3958-y ↗
49. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: Relation to maternal and fetal characteristics10.1002/uog.12331 ↗
50. The future of DNA sequencing10.1038/550179a ↗
51. Benefits and limitations of noninvasive prenatal aneuploidy screening10.1097/01.JAA.0000654208.03441.23 ↗
52. Cherchez la femme: Maternal incidental findings can explain discordant prenatal cell-free DNA se-quencing results10.1038/gim.2017.219 ↗
53. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies10.1001/jama.2015.7120 ↗
54. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism–based noninvasive prenatal test10.1016/j.ajog.2014.10.012 ↗
55. Incidental Detection of Maternal Neoplasia in Noninvasive Prenatal Testing10.1373/clinchem.2017.277517 ↗
56. Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease10.1126/scitranslmed.aan1240 ↗
57. Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies10.1002/uog.14690 ↗
58. (2024, June 03). ACOG Practice Bulletin 226 Clinical Management Guidelines for Obstetrician-Gynecologists Screening for Fetal Chromosomal Abnormalities. Available online: http://journals.lww.com/greenjournal.
59. Too much, too soon? Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond10.1038/gim.2015.23 ↗
60. The role of ultrasound in women who undergo cell-free DNA screening10.1016/j.ajog.2017.01.005 ↗
61. (2016). Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet. Gynecol., 127, e123–e137.10.1097/AOG.0000000000001406 ↗
62. First-trimester screening-biomarkers and cell-free DNA10.1080/14767058.2019.1698031 ↗
63. A new method for sequencing DNA10.1073/pnas.74.2.560 ↗
64. DNA sequencing with chain-terminating inhibitors10.1073/pnas.74.12.5463 ↗
65. Genome sequencing in microfabricated high-density picolitre reactors10.1038/nature03959 ↗
66. Procedure-related complications of amniocentesis and chorionic villous sampling: A systematic review10.1097/01.AOG.0000278820.54029.e3 ↗
67. Rapid Prenatal Diagnosis of Aneuploidy for Chromosomes 21, 18, 13, and X by Quantitative Fluorescence Polymerase Chain Reaction10.1159/000092459 ↗
68. Can amnio-polymerase chain reaction alone replace conventional cytogenetic study for women with pos-itive biochemical screening for fetal Down syndrome?10.1016/S0029-7844(03)00222-9 ↗
69. Complementary Tumor Diagnosis by Single Cell–Based Cytogenetics Using Multi-marker Fluorescence In Situ Hybridization (mFISH)10.1002/cpz1.942 ↗
70. Fluorescence in situ Hybridization (FISH)10.1002/0471143030.cb2204s23 ↗
71. Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors10.1126/science.1359641 ↗
72. Comparative genomic hybridization
73. Recent advances in array comparative genomic hybridization technologies and their applications in human genetics10.1038/sj.ejhg.5201531 ↗
74. Invasive procedures for prenatal diagnosis: Any future left?10.1016/j.bpobgyn.2012.05.007 ↗
75. Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies10.1002/pd.3945 ↗
76. Use of prenatal chromosomal microarray: Prospective cohort study and systematic review and meta-analysis10.1002/uog.12464 ↗
77. Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis10.1056/NEJMoa1203382 ↗
78. Prenatal chromosomal microarray analysis in a diagnostic laboratory; experience with >1000 cases and review of the literature10.1002/pd.3861 ↗
79. Lovrecic, L., Remec, Z.I., Volk, M., Rudolf, G., Writzl, K., and Peterlin, B. (2016). Clinical utility of array comparative genomic hybridisation in prenatal setting. BMC Med. Genet., 17.10.1186/s12881-016-0345-8 ↗
80. Additional value of prenatal genomic array testing in fetuses with isolated structural ultrasound abnor-malities and a normal karyotype: A systematic review of the literature10.1002/uog.12575 ↗
81. Prenatal array comparative genomic hybridization in a well-defined cohort of high-risk pregnancies. A 3-year implementation results in a public tertiary academic referral hospital10.1002/pd.5877 ↗
82. Diagnostic yield of chromosomal microarray analysis in fetuses with isolated increased nuchal translucency: A French multicenter study10.1002/uog.18928 ↗
83. Sequencing technologies—The next generation10.1038/nrg2626 ↗
84. Exome sequencing and whole genome sequencing for the detection of copy number variation10.1586/14737159.2015.1053467 ↗
85. Copy-number variants in clinical genome sequencing: Deployment and interpretation for rare and undiagnosed disease10.1038/s41436-018-0295-y ↗
86. Comparison of Exome and Genome Sequencing Technologies for the Complete Capture of Protein-Coding Regions10.1002/humu.22813 ↗
87. A structural variation reference for medical and population genetics10.1038/s41586-020-2287-8 ↗
88. Kosugi, S., Momozawa, Y., Liu, X., Terao, C., Kubo, M., and Kamatani, Y. (2019). Comprehensive evaluation of structural variation detection algorithms for whole genome sequencing. Genome Biol., 20.10.1186/s13059-019-1720-5 ↗
89. Combining callers improves the detection of copy number variants from whole-genome sequencing10.1038/s41431-021-00983-x ↗
90. Leung, G.K.C., Mak, C.C.Y., Fung, J.L.F., Wong, W.H.S., Tsang, M.H.Y., Yu, M.H.C., Pei, S.L.C., Yeung, K.S., Mok, G.T.K., and Lee, C.P. (2018). Identifying the genetic causes for prenatally diagnosed structural congenital anomalies (SCAs) by whole-exome sequencing (WES). BMC Med. Genom., 11.10.1186/s12920-018-0409-z ↗
91. Correction: An approach to integrating exome sequencing for fetal structural anomalies into clinical practice
92. Qin, Y., Yao, Y., Liu, N., Wang, B., Liu, L., Li, H., Gao, T., Xu, R., Wang, X., and Zhang, F. (2023). Prenatal whole-exome sequencing for fetal structural anomalies: A retrospective analysis of 145 Chinese cases. BMC Med. Genom., 16.10.1186/s12920-023-01697-3 ↗
93. Huang, W., Zhu, X., Sun, G., Gao, Z., and Kong, X. (2023). Whole-exome sequencing in deceased fetuses with ultrasound anomalies: A retrospective analysis. BMC Med. Genom., 16.10.1186/s12920-022-01427-1 ↗
94. Wang, Y., Yin, F., Chai, Y., Jin, J., Zhang, P., Tan, Q., and Chen, Z. (2024). Prenatal diagnosis of fetuses with ultrasound anomalies by whole-exome sequencing in Luoyang city, China. Front. Genet., 14.10.3389/fgene.2023.1301439 ↗
95. Whole exome sequencing in fetuses with isolated increased nuchal translucency: A systematic review and meta-analysis10.1080/14767058.2023.2193285 ↗
96. Prenatal whole-exome sequencing in fetuses with increased nuchal translucency10.1002/mgg3.2246 ↗
97. Incremental yield of whole-genome sequencing over chromosomal microarray analysis and exome se-quencing for congenital anomalies in prenatal period and infancy: Systematic review and meta-analysis10.1002/uog.27491 ↗
98. Micronutrients and intrauterine infection, preterm birth and the fetal in-flammatory response syndrome10.1093/jn/133.5.1668S ↗
99. Epidemiology and causes of preterm birth10.1016/S0140-6736(08)60074-4 ↗
100. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes10.1067/mob.2001.117680 ↗